The tumor suppressor gene p53 - Function and significance in gastroenterology;Das Tumorsuppressorgen p53 - Funktion und Bedeutung in der Gastroenterologie

Zeitschrift fur Gastroenterologie

Volumn 35, Issue 6, 1997, Pages 491-504

  Schoppmeyer, K ^a   Keim, V ^a   Mossner J ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Apoptosis; Cell cycle control; Gastrointestinal tumors; p53; Tumor suppressor gene

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; DNA SEQUENCE; GASTROENTEROLOGY; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PROTEIN DOMAIN; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GASTROINTESTINAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030806936     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (153)

1. Lane DP, Benchimol S. p53: Oncogene or anti-oncogene? Genes Dev 1990; 4: 1-8
2. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 gene in relation to gene evolution. Oncogene 1990; 5: 945-52
3. Hollstein M. Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53
4. Forrester K, Lupold SE, Ott VL et al. Effects of P53 mutant and wild-type p53-mediated transactivation are cell type dependent. Oncogene 1995; 10: 2103-11
5. Lalle P, Moyret-Lalle C, Wang Q et al. Genomic stability and wild-type p53 function of lymphoblastoid cells with germ line p53 mutation. Oncogene 1995; 10: 2447-54
6. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-3
7. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1B-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982; 28: 387-94
8. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9
9. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45
10. Mietz JA, Unger T, Huibregtse JM, Howley PM. The transcriptional transactivation function of wild type p53 is inhibited by SV 40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992; 11: 5013-20
11. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36
12. Oliner JD, Kinzler KW, Meltzer PS, George DL. Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3
13. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992; 89: 7262-6
14. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: Epidemiology study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43: 1365-73
15. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8
16. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig KW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11
17. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491-5
18. Ziegler A, Jonason AS, Leffel DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 730
19. Livingstone RL, White A, Sprouse J et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 1992; 70: 923-34
20. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant P53 alleles. Cell 1992; 70: 937-48
21. Lane DP. Cancer p53, guardian of the genome. Nature 1992; 358: 15-6
22. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6
23. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-6
24. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93
25. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86: 8763-7
26. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 1990; 249: 912-5
27. Mercer WE, Shields MT, Amin M et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild type p53. Proc Natl Acad Sci USA 1990; 87: 6166-70
28. Cheng J, Yee JK, Yeargin J, Friedmann T, Haas M. Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res 1992; 52: 222-6
29. Kern SE, Pietenpol JA, Thiagalingam S et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-30
30. Donehower LA, Harvey M, Slagle BL et al. Mice deficient of p53 developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356: 215-21
31. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046-9
32. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild type but not from oncogenic mutant p53 protein. Genes Dev 1993; 7: 2565-74
33. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 1993; 7: 2556-64
34. Sakamoto H, Lewis MS, Kodama H, Appella E, Sakaguchi K. Specific sequences from the carboxyl terminus of human p53 gene product form antiparallel tetramers in solution. Proc Natl Acad Sci USA 1994; 91: 8974-8
35. Bayle JH, Elenbaas B, Levine AJ. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad Sci USA 1995; 92: 5729-33
36. Raycroft L, Wu H, Lozano G. Transcriptional activation of wild type but not transforming mutants of the p53 anti-oncogene. Science 1990; 249: 1043-51
37. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994; 8: 1235-46
38. White RJ, Jackson SP. The TATA-binding protein: A central role in transcription by RNA Polymerases I, II and III. Trends Genet 1992; 8: 284-8
39. Lu H, Levine AJ. Human TAF II 31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA 1995; 92: 5154-8
40. Seto E, Usheva A, Zambetti GP et al. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 1992; 89: 12028-32
41. Ragimov N, Krauskopf A, Navot N et al. Wild type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors of the TATA motif. Oncogene 1993; 8: 1183-93
42. Mack DH, Vartikar J, Pipas JM, Laimins LA. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 1993; 363: 281-3
43. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-UNA complex: Understanding tumorigenic mutations. Science 1994; 265: 346-55
44. Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K. Role of cysteine residues in regulation of P53 function. Mol Cell Biol 1995; 15: 3892-903
45. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nature Genet 1992; 1: 45-9
46. Kastan MB, Zhan Q, El-Deiry WS et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-97
47. Barak Y, Juven T, Haffner R, Oren M. mdm-2 expression is induced by wild-type p53 activity. EMBO J 1993; 12: 461-8
48. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13: 301-6
49. Chen CY, Oliner JD, Zhan Q et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994; 91: 2684-8
50. Xiao ZX, Chen J, Levine AJ et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-8
51. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25
52. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16
53. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7: 1572-83
54. Xiong Y, Hannon GJ, Zhang H et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4
55. Hunter T. Braking the cycle. Cell 1993; 75: 839-41
56. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-65
57. Spitkovsky D, Steiner P, Gopalkrishnan RV, Eilers M, Jansen-Durr P. The role of p53 in coordinated regulation of cyclin D1 and p21 gene expression by the adenovirus E1A and E1B oncogenes. Oncogene 1995; 10: 2421-5
58. Namba H, Tara H, Tukazaki T et al. Radiation-induced G1 arrest is selectively mediated by the p53-Waf1/Cip1 pathway in thyroid cells. Cancer Res 1995; 55: 2075-80
59. Bond JA, Blaydes JP, Rowson J et al. Mutant p53 rescues human diploid cells from senescene with-out inhibiting the induction of SDI1/WAF1. Cancer Res 1995; 11: 2404-9
60. Waga S, Hannon GJ, Beach D, Stillman B. The P21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-8
61. Li R, Waga S, Hammon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA dependent DNA replication and repair. Nature 1994; 371: 534-7
62. Shaulsky G, Goldfinger N, Ben Zeev A, Rotter V. Nuclear accumulation of p53 is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990; 10: 6565-77
63. Wu Y, Liu Y, Lee L, Miner Z, Kulesz-Martin M. Wildtype alternatively spliced p53: Binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J 1994; 13: 4823-30
64. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875-86
65. Bakalkin G, Yakoleva T, Selivanova G et al. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci USA 1994; 91: 413-7
66. Oberosler P, Hloch P, Ramsperger U, Stahl H. p53-catalyzed annealing of complementary single stranded nucleic acids. EMBO J 1993; 12: 2389-96
67. Wu L, Bayle JH, Elenbaas B, Pavletich NP, Levine AJ. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 1995; 15: 497-504
68. Lowe SW, Schmitt SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9
69. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of a p53 associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993; 53: 4164-8
70. Vaux DL, Weisman IL, Kim SK. Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science 1992; 258: 1955-7
71. Larsen CJ. Le gene BCL2, chef de file d'une famille de genes controlant la mort cellulaire programmé e (apoptosis). Ann Genet 1994; 37: 121-34
72. Wang Y, Szckely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a b-myc-induced T-cell lymphoma line. Oncogene 1993; 8: 3427-31
73. Chiou SK, Rao L, White E. Blc-2 blocks p53 dependent apoptosis. Mol Cell Biol 1993; 14: 2556-63
74. Bissonnette RP, Echeverri F, Mahboubi A, Grenn DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-4
75. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359: 554-6
76. Pietenpol JA, Papadopoulos N, Markowitz S et al. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 1994; 54: 3714-7
77. Guillouf C, Grana X, Selvakumaran M et al. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis unmasks G1 arrest. Blood 1995; 85: 2691-8
78. Silvestrini R, Veneroni S, Daidone MG et al. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504
79. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W. Immunhistochemical analysis of bcl-2 and p53 expression in breast carcinomas: Their correlation with Ki-67 growth fraction. Virchows Arch 1995; 426: 229-33
80. Selvakumaran M, Lin HK, Miyashita T et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: A paradigm for distinct apoptotic pathways. Oncogene 1994; 9: 1791-8
81. Zhan Q, Fan S, Bae I et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994; 9: 3743-51
82. Guillouf C, Rosselli F, Krishnaraju K et al. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage induced apoptosis. Oncogene 1995; 10: 2263-70
83. Hollstein MC, Metcalf RA, Welsh JA et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990; 87: 9958-61
84. Hollstein MC, Peri L, Mandard AM et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: Frequent p53 base substitutions and absence of ras mutations. Cancer Res 1991; 51: 4102-6
85. Stemmermann G, Heffelfinger SF, Noffsinger A et al. The molecular biology of esophageal and gastric cancer and their precursors: Oncogenes, tumor suppressor genes, and growth factors. Hum Pathol 1994; 25: 968-81
86. Parenti AR, Rugge M, Frizzera E et al. p53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pathol 1995; 19: 1418-22
87. Volant A, Nousbaum JB, Giroux MA. p53 accumulation in oesophageal squamous cell carcinomas and precancerous lesions. J Clin Pathol 1995; 48: 531-4
88. Meltzer SJ, Yin J, Huang Y et al. Reduction of homocygosity involving p53 in esophageal cancer demonstrated by the polymerase chain reaction. Proc Natl Acad Sci USA 1991; 88: 4976-80
89. Ounes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study. Gastroenterol 1993; 105: 1637-42
90. Flejou JF, Volant A, Diebold MD et al. Overexpression of protein p53 and Barrett esophagus. A frequent and early event in the course of carcinogenesis. Gastroenterol Clin Biol 1995; 19: 475-81
91. Krishnadath KK, Tilanus HW, van Blankenstein M, Bosman FT, Mulder AH. Accumulation of p53 in normal, dysplastic and neoplastic Barrett's oesophagus. J Pathol 1995; 175: 175-80
92. Casson AG, Kerkvliet N, O'Malley F. Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol 1995; 60: 5-11
93. Sauter ER, Keller SM, Erner SM. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 1995; 58: 269-73
94. Moreira LF, Naomoto Y, Hamada M, Kawikawa Y, Orita K. Assessment in apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Res 1995; 15: 639-44
95. Nabeya Y, Loganzo F Jr. Maslak P et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995; 64: 37-46
96. Imazeki F, Omata M, Nose H et al. Gene mutations in gastric and esophageal cancers. Gastroenterol 1992; 103: 892-6
97. Craanen ME, Blok P, Dekker W, Offerhaus GJ, Tytgat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995; 36: 848-52
98. Yamada Y, Yoshida T, Hayashi K et al. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derives from metastases. Cancer Res 1991; 51: 5800-5
99. Kim JH, Takahashi T, Chiba I et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 1991; 83: 938-43
100. Oiwa H, Maehara Y, Ohno S. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995; 75: 1454-9
101. Matozaki T, Sakamoto C, Matsuda K et al. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem Biophys Res Commun 1992; 182: 215-23
102. Lin JT, Wu MS, Shun CT et al. Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein. Cancer Res 1995; 55: 1428-30
103. Ranzani GN, Luinetti O, Padovan LS et al. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 1995; 4: 223-31
104. Kitayama Y, Sugimura H, Tanaka M, Nakamura S, Kino I. Expression of p53 and flow cytometric DNA analysis of isolated neoplastic glands of the stomach: An application of the gland isolation method. Virchows Arch 1995; 426: 557-62
105. Nishisho I, Nakamura Y, Miyoshi Y et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253: 665-9
106. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67
107. Schmutte C, Yang AS, Beart RW, Jones PA. Base excision repair of U:G mismatches at a mutational hot spot in the p53 gene is more efficient than base excision repair of T:G mismatches in extracts of human colon tumors. Cancer Res 1995; 55: 3742-6
108. Gudjonsson B, Cancer of the pancreas. Cancer 1987; 60: 2283-303
109. Barton CM, Staddon SL, Hughes CM et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-82
110. Casey G, Yamanaka Y, Friess H et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Letters 1993; 69: 151-60
111. Kalthoff H, Schmiegel W, Roeder C et al. p53 and k-ras alterations in pancreatic epithelial lesions. Oncogene 1993; 8: 289-98
112. Zhang SY, Ruggeri B, Agarwal P et al. Immunhistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118: 150-4
113. Yokoyama M, Yamanaka Y, Friess H, Büchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994; 14: 2477-83
114. Nakamori S, Yashima K, Murakami O et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jap J Cancer Res 1995; 86: 174-81
115. diGiuseppe JA, Hruban RH, Goodman SN. Overexpression of p53 protein in adenocarcinoma of the pancreas. Anatomic Path 1994; 101: 684-8
116. Simon B, Weinel R, Höhne M et al. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic cancer. Gastroenterol 1994; 106: 1645-51
117. Redston MS, Caldas C, Seymour AB. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA micro-deletions. Cancer Res 1994; 54: 3025-33
118. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78
119. Konishi Y, Mizumoto K, Kitazawa S et al. Early ductal lesions of pancreatic carcinogenesis in animals and humans. Int J Pancreatol 1990; 9: 83-9
120. Obara T, Saitoh Y, Maguchi H et al. Multicentric development of pancreatic intraductal carcinoma through atypical papillary hyperplasia. Hum Pathol 1992; 23: 82-5
121. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994; 145: 1291-5
122. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations of the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994; 58: 185-91
123. Pellegata NS, Sessa F, Renault B et al. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-60
124. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-3
125. Lee CS, Rush M, Charalambous D, Rode J. Immunhistochemical demonstration of the p53 tumour suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 1993; 8: 465-9
126. van Es JM, Polak MM, van den Berg FM, Ram soekh TB. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: Mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol 1995; 48: 218-22
127. Marxsen J, Schmiegel W, Roder C et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994; 70: 1031-4
128. Laurent-Puig P, Lubin R, Semhoun-Ducloux S et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995; 36: 455-8
129. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 71: 429-37
130. Shi CY, Phang TW, Lin Y et al. Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. Br J Cancer 1995; 72: 146-9
131. McGlynn KA, Rosvold EA, Lustbader ED et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995; 92: 2384-8
132. Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci USA 1995; 92: 11215-9
133. Ueda H, Ullrich SJ, Gangemi JD et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995; 9: 41-7
134. Takada S, Tsuchida N, Kobayasbi M, Koike K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepato-carcinogenesis. J Cancer Res Clin Oncol 1995; 121: 593-601
135. Nagao T, Kondo F, Sato T, Nagato Y, Kondo Y. Immunhistochemical detection of aberrant p53 expression in hepatocellular carcinoma: Correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Hum Pathol 1995; 26: 326-33
136. Ojanguren I, Ariza A, Castella EM et al. p53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. Histopathology 1995; 26: 63-8
137. Ng IO, Lai EC, Chan AS, So MK. Overexpression of p53 in hepatocellular carcinomas: A clinico-pathological and prognostic correlation. J Gastroenterol Hepatol 1995; 10: 250-5
138. Ohashi K, Nakajima Y, Kanehiro H et al. Ki-ras mutations and p53 protein expression in intrahepatic cholangiocarcinoinas: Relation to gross tumor morphology. Gastroenterol 1995; 109: 1612-7
139. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology 1995; 22: 774-9
140. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 1993; 170: 67-72
141. Wee A, Teh M, Raju GC. Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. J Clin Pathol 1994; 47: 453-6
142. Oohashi Y, Watanabe H, Ajioka Y, Hatakeyama K. p53 immunostaining distinguishes malignant from benign lesions of the gall bladder. Pathol Int 1995; 45: 58-65
143. Wistuba II, Sugio K, Hung J et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995; 55: 2511-5
144. Hall PA, Lane DP. p53 in tumor pathology: Can we trust immunohistochemistry? - Revisited. J Pathol 1994; 172: 1-4
145. Müller M, Volkmann M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1994; 330: 865
146. Li FP, Garber JE, Friend SH et al. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 1992; 84: 1156-60
147. Friedmann T. Gene therapy of cancer through restoration of tumor-suppressor function. Cancer 1992; 70: 1810-7
148. Kinzler KW, Vogelstein B. Cancer therapy meets P53. N Engl J Med 1994; 331: 49-50
149. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 5742-6
150. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67
151. Chin KV, Ueda K, Pastan I, Gottesman M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992; 255: 459-62
152. Strauss BE, Haas M. The region 3′ to the major transcriptional start site of the MDR1 down-stream promoter mediates activation by a subset of mutant p53 proteins. Biochem Biophys Res Commun 1995; 217: 333-40
153. Hollstein M, Shomer B, Greenblatt M et al. Somatie point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucl Acid Res 1996; 24: 141-6